Search

Displaying results 1411 - 1420 of 6835 in total
  1. Indication

    Periungual Warts

    go.drugbank.com/conditions/DBCOND0077510
    Drugs: Cantharidin
    Synonyms: Periungual wart, Periungual wart (disorder)
  2. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … to provide passive immunization against RSV infection as an alternative means of protection.

  3. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    Marketed by Recordati Rare Diseases Inc., CYSTADROPS® reduce the burden of multiple frequent medications normally administered to those with cystinosis.[L15601] … [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis.

  4. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].

  5. Drug

    Perindopril

    go.drugbank.com/drugs/DB00790
    ApprovedInvestigational

    Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial … It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration.

    Mixtures: PERINDO/IN RAT T 5/1.25, PERINDO/IN RAT T 5/1.25
  6. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses … [A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities

  7. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.

  8. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  9. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

  10. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin.